

Peter Mol is a principal assessor at the Dutch Medicines Evaluation Board and a member (vice chair) of EMA's Scientific Advice Working Party. He is chair of the EMA Cross-Committee Task force on Registries

(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000658.jsp&mid=WC0b01ac0580961211).

He is also an assistant professor at the University Medical Center Groningen. His research interest is in the area of regulatory science; from new tools to optimize regulatory decision-making to improving knowledge transfer with a specific interest in risk communication and medication safety. His key publications are on the impact of Direct Healthcare Professional Communications on drug utilization, regulatory decision-making and on various interventions to improve medication safety.